The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Tandem Meetings 2023 | Characteristics of patients with B-cell malignancies treated with tisa-cel in the outpatient setting
Nausheen Ahmed, MD, University of Kansas Medical Center, Westwood, KS, outlines the main differences between patients with B-cell malignancies treated with tisagenlecleucel (tisa-cel) in the outpatient versus inpatient settings. Dr Ahmed explains that patients treated in the outpatient setting had more normal lactate dehydrogenase (LDH) levels and had a lower Charlson Comorbidity Index (CCI) score. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
BMS: Advisory Board; KUMC – Kite Pharma: Research Funding
